// App-Quantinova.ai

4019 : Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.

Researchers

Presenter

  • Shukui Qin

Principal Investigators

  • N/A

Medical Centers

  • Nanjing Bayi Hospital, Nanjing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Apatinib

Outcome

  • Positive

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved